CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Chronic Lymphocytic Leukemia
Related studies linked through entity extraction aliases.
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE3
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
- Status
- TERMINATED
- Phase
- PHASE2
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Status
- RECRUITING
- Phase
- PHASE1
Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL
- Status
- WITHDRAWN
- Phase
- PHASE1
Observational Study of Ibrutinib Use in CLL
- Status
- UNKNOWN
- Phase
- N/A
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
- Status
- TERMINATED
- Phase
- PHASE2
Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
- Status
- TERMINATED
- Phase
- PHASE1
Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC Study
- Status
- COMPLETED
- Phase
- N/A
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2